T细胞受体基因转导的T细胞在肿瘤治疗中的研究进展  

Research Progress of T cell Receptor Gene Transduction in Tumor Therapy

作　　者：徐道俊 周巧 何志宇 李美玲 司俊波 XU Dao-jun;ZHOU Qiao;HE Zhi-yu;LI Mei-ling;SI Jun-bo(CYTOCRAFT Biopharmaceutical Co.,Ltd.,Chengdu 610036,China)

机构地区：[1]赛德特生物制药有限公司,四川成都610036

出　　处：《药物生物技术》2022年第2期192-200,共9页Pharmaceutical Biotechnology

摘　　要：T细胞受体基因转导的T细胞(T-cell receptor genetically transdused T cells,TCR-T)作为肿瘤过继性细胞治疗(Adoptive cell therapy,ACT)技术两大最新的免疫细胞技术之一,展现出低毒、高效、安全等特点,特别在实体瘤临床运用中展现出很好的疗效,并且对慢性感染和自身免疫具有同等希望。尽管嵌合抗原受体T细胞疗法(CAR-T)已对B细胞谱系的血液系统恶性肿瘤产生了显著疗效,但大多数实体瘤均无法对嵌合抗原受体T细胞产生明显反应。文章仔细分析了使用T细胞受体基因转导的T细胞疗法的临床试验以及目前此技术的机遇与挑战,主要对T细胞受体基因转导的T细胞在肿瘤治疗中的研究进展进行综述。T-cell receptor genetically transdused T-cells(TCR-T),as one of the two newest immune cell technologies of adoptive cell therapy(ACT)have demonstrated technology.It shows the characteristics of low toxicity,high efficiency and safety,especially in the clinical use in solid tumors,and hold equal promise for chronic infections and autoimmunity.Although chimeric antigen receptor T-cell therapy(CAR-T)has produced significant efficacy in hematologic malignancies of the B-cell spectrum,most solid tumors fail to respond significantly to chimeric antigen receptor T-cells.The article carefully analyzes the rationale for using T-cell receptor genetically transdused T-cells therapy,clinical trials,and the current opportunities and challenges of this technology,focusing on a review of research advances in T-cell receptor genetically transdused T-cells in tumor therapy.

关 键 词：T细胞受体基因转导的T细胞 免疫治疗 过继性细胞治疗 肿瘤微环境 实体肿瘤 TCR临床试验 

分 类 号：R730.51[医药卫生—肿瘤]